[Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)]
- PMID: 23528596
[Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)]
Abstract
The working experience of the Moscow oblast center for multiple sclerosis is analyzed. Along with standard methods of treatment efficacy evaluation, a cytokines (tumor necrosis factor alpha, gamma-interferon, interleukins 10 and 17) measurement, a morphological study of CD4 and CD8 lymphocytes with cell microelectrophoresis, a complex of morphometric and optic cell parameters using laser computed phase-interference microscopy and cell optic coherent tomography of the eye's retina are used. Preliminary results of the efficacy of these methods are presented.
Similar articles
-
[Disease modifying drugs in multiple sclerosis and pregnancy].Med Clin (Barc). 2012 Sep 22;139(7):316-8. doi: 10.1016/j.medcli.2012.04.021. Epub 2012 Jun 27. Med Clin (Barc). 2012. PMID: 22743277 Spanish. No abstract available.
-
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Drugs. 2012. PMID: 22642799 Review.
-
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. JAMA Neurol. 2015. PMID: 25665031
-
[Update on current care guidelines: multiple sclerosis].Duodecim. 2013;129(5):548-9. Duodecim. 2013. PMID: 23520898 Review. Finnish.
-
Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies.Nat Rev Neurol. 2015 Jun;11(6):316-7. doi: 10.1038/nrneurol.2015.59. Epub 2015 Apr 21. Nat Rev Neurol. 2015. PMID: 25896088 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials